Product/Composition:- | Levodopa + Carbidopa |
---|---|
Strength:- | IR: 100 mg/25 mg , 250 mg/25 mg; ER: 200 mg/50 mg |
Form:- | Tablets |
Reference Brands:- | Sinemet®(US & EU); Rytary®, Parcopa®, Duodopa® |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Levodopa-Carbidopa treats Parkinson’s disease, available in 100/25 mg, 250/25 mg, and 200/50 mg tablets. Brands include Sinemet®, Rytary®, and Duodopa®. Pharma B2B platforms enable global sourcing from GMP-certified manufacturers, ensuring regulatory-compliant, high-quality bulk supply for hospitals, pharmacies, and neurology care providers
Levodopa-Carbidopa is a first-line treatment for Parkinson’s disease, available in various oral formulations including immediate-release, extended-release, and orally disintegrating tablets. It is also supplied as Duodopa® intestinal gel for advanced stages. Common strengths include 100/25 mg, 250/25 mg, and 200/50 mg. Leading brands include Sinemet®, Rytary®, and Duodopa® in both the US and EU markets. Levodopa restores dopamine, while Carbidopa enhances its CNS availability and reduces side effects. Pharma B2B marketplaces connect global buyers with GMP-compliant manufacturers of Levodopa-Carbidopa, offering regulatory-compliant, bulk supply solutions for hospitals, distributors, and neurology-focused pharma procurement.